Key Points
- James Peyer, a major shareholder in Sensei Biotherapeutics, sold multiple tranches totaling 27,907 shares in early December (including 3,105 shares on Dec. 8 at $8.59), generating roughly $287,280 in proceeds and reducing his stake to 158,254 shares.
- Sensei's shares traded around $8.36 mid-day with a market cap of $10.54 million, negative earnings (P/E -0.44), a 52-week range of $5.00–$18.35, and an analyst consensus of "Moderate Buy" with a surprisingly high average price target of $55.00.
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE - Get Free Report) major shareholder James Peyer sold 3,105 shares of the company's stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $8.59, for a total value of $26,671.95. Following the completion of the transaction, the insider directly owned 158,254 shares of the company's stock, valued at approximately $1,359,401.86. This trade represents a 1.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
James Peyer also recently made the following trade(s):
- On Tuesday, December 9th, James Peyer sold 3,507 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $7.96, for a total value of $27,915.72.
- On Friday, December 5th, James Peyer sold 16,295 shares of Sensei Biotherapeutics stock. The stock was sold at an average price of $11.50, for a total value of $187,392.50.
- On Thursday, December 4th, James Peyer sold 5,000 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $9.06, for a total transaction of $45,300.00.
Sensei Biotherapeutics Price Performance
Shares of SNSE stock traded down $0.21 during mid-day trading on Thursday, hitting $8.36. The company had a trading volume of 17,293 shares, compared to its average volume of 62,780. The stock's 50 day moving average price is $9.83 and its 200-day moving average price is $8.63. Sensei Biotherapeutics, Inc. has a 52-week low of $5.00 and a 52-week high of $18.35. The company has a market capitalization of $10.54 million, a P/E ratio of -0.44 and a beta of 0.32.
Sensei Biotherapeutics (NASDAQ:SNSE - Get Free Report) last posted its earnings results on Friday, November 14th. The company reported ($3.62) earnings per share for the quarter, beating the consensus estimate of ($4.11) by $0.49. On average, equities research analysts expect that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on SNSE. HC Wainwright cut Sensei Biotherapeutics from a "buy" rating to a "neutral" rating in a report on Thursday, October 30th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sensei Biotherapeutics in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $55.00.
Get Our Latest Stock Report on SNSE
Sensei Biotherapeutics Company Profile
(
Get Free Report)
Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
